Princess Alexandra Hospital Radiation OncologyAnnual Research Report

Produced by Professor Sandro V PorcedduDirector of Radiation Oncology Research, Cancer Services, Metro South Health.

2018

Radiation OncologyIpswich Rd Campus Princess Alexandra Hospital

Message from Director of Research Radiation Oncology Princess Alexandra HospitalProfessor Sandro Porceddu

It has been another outstanding year of research for the Princess Alexandra Hospital Radiation Oncology Department. In 2018 the department published 35 peer-review articles and presented at over 100 scientific conferences, which included presentations in over 20 countries, confirming our global reach.

We continue to proudly foster junior members through research higher degrees, with 5 members enrolled in either masters degrees or PhD’s. The high quality research undertaken within the unit was rewarded with 10 awards, and $3.2M in grant funding.

There is no doubting the PAH Radiation Oncology Department’s leadership and contribution to high quality innovative and practice-defining research as part of Metro South Health.

We wish to take this opportunity to acknowledge our scientific collaborators and researchers, funding bodies, donors and the pafoundation for their continued support.

Sandro V Porceddu

Director, Radiation Oncology ResearchPrincess Alexandra Hospital

Introduction

1

Message from Manager of Cancer Trials Unit (CTU)Division of Cancer Services – Princess Alexandra HospitalAdrienne See

The combined resources of the ROPART and ROPAIR Cancer Trials Offices has resulted in a very busy year with seven new studies being added to the CTU Radiation Oncology Trials portfolio (4 Phase II, 3 Phase III) at the Ipswich Road and Raymond Terrace campuses. This has culminated in 37 new patients being recruited to the 15 studies currently open to accrual. Six studies closed to recruitment during 2018. Another 4 studies closed to follow up and are awaiting final analysis including the TROG 11.03 P-LUNG Study. Emerging technologies and combination therapies have been at the forefront of the changing Radiation Oncology trials landscape. Such studies such as “HART” (Heart Avoiding Radiation Therapy) and SC.24 (Phase II/III study comparing SBRT vs. Conventional XRT in patients with spinal metastases) push boundaries to improve “pure” radiation oncology techniques, whilst other new studies such SARC032 (A Randomized Trial of Pembrolizumab & Radiotherapy versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity) and “OUTRUN” (Phase II trial of Osimertinib with or without Stereotactic Radiosurgery for EGRF mutates NSCLC with brain metastases) continue to embrace the emergence of combination therapy with immunotherapy agents. This emergence of combined therapies has resulted in cross-discipline partnerships with our medical oncology and haematology colleagues.

Another collaboration which has been brokered with the Australian Prostate Cancer Research Centre Queensland (APCRC-Q) offers coordinator assistance to increase recruitment in their respective trials. This is a very exciting alliance and could result in a long-term model to support other smaller research groups within PAH.

Adrienne SeeManager, Clinical Trials UnitCancer ServicesPrincess Alexandra Hospital

2

Cancer Services Clinical Trials Unit Report

Awards and Prizes

Howard Liu• RO Uhr Clarke Bursary award for 2017.

• Impact of smoking history on locoregional recurrence-free, distant metastasis-free survival and overall survival in Human Papillomavirus (HPV)-associated oropharyngeal cancer (OPC) treated with definitive (chemo) radiotherapy.

Poster of Distinction, American Head and Neck Society Meeting, Maryland, USA, April 2018.

Kate Brennan, Elizabeth Brown, Jodie Nixon, Lauren Mahoney, Susan Wilton• The magic power of our hands: Using manual lymphatic drainage to support the radiotherapy journey for head

and neck cancer. Best clinical poster prize, Australasian Lymphology Conference, Brisbane, Australia, May 2018.

Erin Johns• Optimising Dose Beyond the Target in Brain Stereotactic Radiotherapy. Best paper, Pinnacle Users Group Meeting, Melbourne, Australia, November 2018.

Jessica Boersen• ASMIRT Early Careers International Travel Scholarship 2018.

• Dose de-escalation for HPV-positive squamous cell carcinoma: is it viable. Best student oral presentation, Annual Scientific Meeting of Medical Imaging and Radiation Therapy (ASMIRT),

Canberra, Australia, March 2018.

David Pryor• Preliminary Results of a Multicentre Phase 2 Study of SBRT Boost for Intermediate / High Risk Prostate Cancer

(PROMETHEUS). Best Scientific Paper Presentation, Australian and New Zealand Urogenital and Prostate Cancer Trials Group Annual Scientific Meeting, Sydney, Australia, July 2018.

• Preliminary Results of a Multicentre Phase 2 Study of SBRT Boost for Intermediate / High Risk Prostate Cancer (PROMETHEUS).

Best Radiation Oncology Scientific Paper Presentation. Royal Australian and New Zealand College of Radiologists Annual Scientific Meeting, Canberra, Australia, October 2018.

Bena Brown• Queensland Health Speech Pathology Advisory Committee (QHSPAC) Excellence Award for Research and

Knowledge Translation.

Bena Brown, Laurelie Wishart• Finalists eHealth Hacking Health: “ScreenIT: Online Screening, Integrated Care”, eHealth Expo 2018. Brisbane,

Australia, June 2018.

3

Individual Achievements

Grants Funding

Projects and Recipients

1. The Cancer Wellness and Research Initiative: A Pilot implementation to investigate consumer engagement, feasibility, and service level efficiency.

Innovation Grant, Princess Alexandra Hospital Research Foundation – $200,000 Nixon J, McKinnell E, Cartmill B, Wall L, Walpole E, Stone L, Chan R, Whitehead M, Ward E, Puffett A, Gardner T,

Hanley B, Miller E.

2. Evaluation of a telehealth intervention for delivering psychosocial support to people with brain tumour and their families.

NHMRC Project Partnership funding ($376,857.98) and CCQ cash contribution ($106,000). Ownsworth T, Chambers SK, Aitken JF, Foote M, Shum D, Gordon LG, Pinkham M.

3. Pilot study of 18F-Fluoroethyl-L-Tyrosine (FET) hybrid positron emission tomography (PET) and magnetic resonance imaging (MRI) assessment of treatment response in brain malignancies.

Metro South Health Research Support Scheme Novice Researcher Small Grant – $23,100. Chacko A, Pinkham M, Foote M, Law P, Watkins T.

4. A Phase Ib, single centre, open label study of a therapeutic Human Papillomavirus (HPV) DNA vaccine co-administered with anti-PD-L1 immunotherapy, durvalumab (MedI4736), for recurrent and/or metastatic HPV-related head and neck cancer.

Metro South Health Research Support Scheme Project Grant – $100,000. Porceddu S, Frazer I, Ladwa R, Panizza B.

5. Effect of sugar consumption on glioblastoma progression and response to therapy. QUT IHBI TRI Seed Funding Scheme – $10,000. Bartlett S, Pinkham M, Mazzieri R, Belmer A, Dolcetti R.

6. Liver MaP – A Prospective Pilot Study of a Novel PET/MRI Evaluation of Regional Liver Function to Guide Surgery and Stereotactic Radiation Therapy for Hepatocellular Carcinoma.

Metro South Health Research Support Scheme Project Grant – $100,000. Pryor D, Fawcett J, Saad N, Lee Y, Stuart K, Dowling J, Thomas P.

7. Novel Integration of New prostate radiation schedules with adjuvant Androgen deprivation (NINJA). Cancer Australia Priority-driven Collaborative Cancer Research Scheme – $600,000. Pryor D, Martin J, Keall P, Siva S, Greer P, Christie D, Moore K, Dowling J.

8. mFOLFIRINOX and STEreotactic body radiotherapy (SBRT) for pancreatic cancer with high-risk and Locally AdvaNced disease (MASTERPLAN): a multicentre, randomised phase II study of the Australian Gastrointestinal Trials Group (AGITG).

Medical Research Future Fund Project Grant – $1,512,000. Kneebone A, Samra J, He L, Nguyen NQ, Goldstein D, Apte M, Barbour A, Oar A, Chander S, Espinoza D, Pryor D.

9. Head & neck lymphoedema treatment: An examination and development of current standards of care. PA Research Foundation Grant 2019 – $100,000 for 1 year. Pigott A, Nixon J, Cartmill B, Porceddu S, McCann A, McPhail S, Jeans C, Trevethan M, Panizza B

10. Improving cardiovascular health outcomes in women undergoing irradiation for breast cancer; investigating new cardiac imaging modalities and reviewing cardiac structure injury from radiation therapy.

PA Research Foundation Grant 2019 – $100,000 for 1 year. Lehman M, Ng A, Dong X, Galloway G, Harvey J, Mai T, Browne P, Beaton N, Sharma H.

4

Research in Focus

5

Improving cardiovascular health outcomes in women undergoing irradiation for breast cancer; investigating new cardiac imaging modalities and reviewing cardiac structure injury from radiation therapy.

The early detection of breast cancer and improvements in treatment has led to an increased number of women surviving or living with breast cancer. A proportion of these women are at risk of developing complications related to their cancer treatment, including heart disease. This possibility is increased because breast cancer & heart disease share common risk factors. Attention needs to turn to interventions that can improve the quality of survival of these women.

Radiation therapy delivered to the breast or chest wall reduces the risk of breast cancer recurrence and improves overall survival. However, an increased incidence of heart disease has been observed with older radiation therapy techniques. The introduction of new technology, especially deep inspiration breath hold techniques, significantly reduces the radiation dose received by the heart but does not completely stop it.

This study will evaluate new technology in assessing the heart with the aim of identifying changes in heart structure and function at an early reversible stage. A prospective patient register will be established to identify potential markers of heart damage. A review of patients who have received radiation therapy will determine whether radiation delivered to specific segments of the heart is associated with an increased risk of heart disease.

Head and neck lymphoedema treatment: An examination and development of current standards of care.

This project will investigate swelling of the head and neck after treatment for head and neck cancer. Head and neck swelling (lymphoedema) is highly visible, can be uncomfortable and may cause difficulty with functions like swallowing, breathing and speaking. There is limited research available to assist understanding of this condition or to guide its treatment.

The project is designed as a prospective observational study of the development of acute head and neck lymphoedema in a head and neck cancer population with an embedded randomised controlled trial for participants who go on to develop chronic lymphoedema. Swelling in the neck, chin and face (external structures) will be examined, as well as structures inside the mouth and throat (internal structures).

The first part of the study will seek to investigate which patients develop acute head and neck lymphoedema after cancer treatment and whether it resolves during the recovery phase. The second part of the study will investigate the lymphoedema therapy provided to those people who continue to have problematic head and neck lymphoedema after their cancer treatment. Multiple therapy modalities are used to treat head and neck lymphoedema but there is little research to inform which modalities are most effective. The second part of this project involves a randomised controlled trial comparing two different therapy modalities for the treatment of head and neck lymphoedema: manual lymphatic drainage (massage) and compression.

Liver MaP – A Prospective Pilot Study of a Novel PET / MRI Evaluation of Regional Liver Function to Guide Surgery & Stereotactic Radiation Therapy for Hepatocellular Carcinoma.

This research project will use a combination of dynamic MRI and PET scans using a new radiotracer called FDGal to create a map detailing which parts of a patient’s liver have the best function. The Liver MaP may allow more patients to safely undergo resection of their liver tumour. For patients undergoing stereotactic radiation therapy the Liver MaP could be used to tailor treatment by intentionally shaping the dose away from the well-functioning liver segments whilst maintaining high doses to the tumour. This is anticipated to result in more patients being appropriately selected for curative treatments and a lower risk of post-treatment liver failure.

Research in Higher Degrees

6

Masters Projects

1. Alisha Wintour Development and Evaluation of an Information Pamphlet for HPV Positive Oropharyngeal Cancer patients. Queensland University of Technology. Supervisors - E Brown, SV Porceddu, P Yates, S Chambers.

2. Erin Johns Investigating brain low dose wash in the treatment of stereotactic radiotherapy for singular brain metastases. Queensland University of Technology. Supervisors – T Barry, M Pinkham, C Hargrave, L Nissen.

3. Christopher Noble EPR Dosimetry for Measuring Very Small Fields in Modern Radiotherapy. Queensland University of Technology. Supervisors - B Perrett, E Horgan.

PhD Projects

4. Alana Hutchison Utilising dosimetric information to enhance the clinical management of dysphagia in patients undergoing

(chemo)radiotherapy for head and neck cancer (HNC). University of Queensland School of Health and Rehabilitation Services. Supervisors - B Brown, L Wishart, E Ward.

5. Jodie Nixon Distress in Head and Neck Cancer: Addressing the problem, supporting the patient, enhancing health

professional engagement. University of Queensland School of Health and Rehabilitation Services. Supervisors - B Brown, J Turner, A Pigott.

Presentations

7

1. Liu HY, Bernard A, Brown E, Tam L, Foote M, Milne R, McGrath M, Rahbari R, Cartmill B, Panizza B, Porceddu SV. Impact of smoking history on locoregional recurrence-free, distant metastasis-free survival and overall survival in Human Papillomavirus (HPV)-associated oropharyngeal cancer (OPC) treated with definitive (chemo) radiotherapy. American Head and Neck Society Annual Meeting, Maryland, USA, April 2018. Poster Presentation.

2. Brown E. Exacting measures: comparing two imaging modalities for intracranial stereotactic radiotherapy – Annual Scientific Meeting of Medical Imaging and Radiation Therapy (ASMIRT), Canberra, Australia, March 2018. Oral Presentation.

3. Browne P. DIBH PRIME investigates: Predictive factors, intrafraction motion and patient experience. Annual Scientific Meeting of Medical Imaging and Radiation Therapy (ASMIRT), Canberra, Australia, March 2018. Oral Presentation.

4. Lambrecht B. A Dosimetric study evaluating different treatment techniques for whole breast radiotherapy. Annual Scientific Meeting of Medical Imaging and Radiation Therapy (ASMIRT), Canberra, Australia, March 2018. Oral Presentation.

5. Frewen H. Failure modes and effects analysis in a paperless radiotherapy department. Annual Scientific Meeting of Medical Imaging and Radiation Therapy (ASMIRT), Canberra, Australia, March 2018. Oral Presentation.

6. Boersen J. Dose de-escalation for HPV-positive squamous cell carcinoma: is it viable? Annual Scientific Meeting of Medical Imaging and Radiation Therapy (ASMIRT), Canberra, Australia, March 2018. Oral Presentation.

7. Pinkham M. Invited speaker. Advances in radiotherapy technology to reduce toxicity. Cancer Nursing Society of Australia 2018 Congress, Brisbane, Australia, June 2018. Oral Presentation.

8. Brown E. Invited speaker. Development of a predictive radiotherapy approach to head and neck cancer. Cancer Nursing Society of Australia 2018 Congress, Brisbane, Australia, June 2018. Oral Presentation.

9. Brown E. Invited speaker. Adaptive radiation therapy. ACPSEM Deforming to best practice Seminar, Newcastle, Australia, June 2018. Oral Presentation.

10. Pryor D. Invited Speaker. Hypofractionation in prostate cancer radiotherapy. Uro-oncology Symposium, Gold Coast, Australia, August 2018. Oral Presentation.

11. Pryor D, Sidhom M, Arumugam S, Bucci J, Gallagher S, Smart J, Grand M, Greer P, Keats S, Wilton L, Martin J. Preliminary Results of a Multicentre Phase 2 Study of SBRT Boost for Intermediate/High Risk Prostate Cancer (PROMETHEUS). ANZUP ASM, Sydney, Australia, July 2018. Oral Presentation.

12. Pryor D, Sidhom M, Arumugam S, Bucci J, Gallagher S, Smart J, Grand M, Greer P, Keats S, Wilton L, Martin J. Preliminary Results of a Multicentre Phase 2 Study of SBRT Boost for Intermediate/High Risk Prostate Cancer (PROMETHEUS). 19th Asia-Pacific Prostate Cancer Conference, Brisbane, Australia, August 2018. Oral Presentation.

13. Siva S, Bressel M, Sandhu S, Tran B, Mooi J, Lewin J, Loi S, Toner G, Moon D, Goad J, Shaw M, Chander S, Eade T, Guminksi A, Dasantha J, Pryor D, Cuff K, Wood S, Lawrentschuk N, Murphy D.

An interim safety analysis of combination stereotactic ablative body radiotherapy (SABR) with adjuvant anti-PD1 immunotherapy in oligometastatic renal cell carcinoma. ANZUP ASM, Sydney, Australia, July 2018. Oral Presentation.

Presentations

8

14. Jameson M, Dowling J, Faustino J, Cloak K, Sidhom M, Martin J, De Leon J, Berry M, Pryor D, Holloway L. PO-0823: TRAC: Automated atlas based machine learning QA of contouring accuracy for the PROMETHEUS trial. ESTRO, Barcelona, Spain, April 2018. Poster Presentation.

15. Joshi A, Rhee H, Pryor D, Lehman M, McKenzie I, Munns J, Malone G, Chung E, Heathcote P, Preston J, Lawson M, Wood S, Gustafson S, Miles K, Vela I. The Journal of Urology. 199(4):e731. April 2018. American Urological Association Annual Meeting, San Francisco, USA, May 2018. Poster Presentation.

16. Stuart KA, Liu H, McLean K, Pryor D. Early Australian experience with Stereotactic Body Radiation Therapy (SBRT) in the management of hepatocellular carcinoma: Efficacy and toxicity. Gastroenterology Society of Australia Scientific Meeting, Brisbane, Australia, September 2018. Poster Presentation.

17. Pryor D, Sidhom M, Arumugam S, Bucci J, Gallagher S, Smart J, Grand M, Greer P, Keats S, Wilton L, Martin J. Preliminary Results of a Multicentre Phase 2 Study of SBRT Boost for Intermediate / High Risk Prostate Cancer (PROMETHEUS). RANZCR ASM, Canberra, Australia, October 2018. Oral Presentation.

18. Barbour AP, Brosda S, Wijnhoven B, Van Hootgem S, Lanschot JJB, Barbour S, Lagarde S, Krause L, Pryor D, Thomas J, Walpole ET, Van der Gaast A, Smithers M. Neoadjuvant therapy for esophageal adenocarcinoma: A propensity score-matched comparison of paclitaxel and carboplatin chemoradiotherapy with cisplatin and 5-fluoruracil-based chemo - or chemoradiotherapy. ESMO 2018 Congress, Munich, Germany, October 2018. Poster Presentation.

19. Pryor D, Liu H, Lee Y, McLean K, Legget D, Fawcett J, Hodgkinson P, Stuart KA. Efficacy and Toxicity of Stereotactic Radiation Therapy in Early and Advanced Stage Hepatocellular Carcinoma. AGITG 20th Annual Scientific Meeting, Brisbane, Australia, November 2018. Poster Presentation.

20. Faustino MJ, Jameson MG, Dowling JA, Cloak K, Sidhom M, Martin J, De Leon J, Berry M, Pryor D, Holloway LC. Automated atlas-based QA of clinical trial contouring to reduce the greatest uncertainty in RT. ESTRO Asia, Singapore, December 2018. Oral Presentation.

21. Martin J, Bucci J, Arumugam S, Gallagher S, Smart J, Grand M, Greer P, Keats S, Wilton L, Sidhom M, Pryor D. Preliminary Results of a Multicentre Study of Stereotactic Radiotherapy Boost for Prostate Cancer. ESTRO Asia, Singapore, December 2018, Oral Presentation.

22. Pryor D. Invited Speaker. Stereotactic Radiotherapy for Oligometastases. Brisbane Cancer Conference, Brisbane, Australia, November 2018. Oral Presentation.

23. Pryor D. Invited Speaker. Emerging role for stereotactic radiotherapy in liver cancers. Brisbane Cancer Conference, Brisbane, Australia, November 2018. Oral Presentation.

24. Pryor D. Invited Speaker. Stereotactic radiotherapy for hepatocellular carcinoma. Stereotactic Interest Group of Australia SABR symposium, Melbourne, Australia, November 2018. Oral Presentation.

25. Pryor D. Invited Speaker. Stereotactic radiotherapy for spine metastases; challenging cases. Stereotactic Interest Group of Australia SABR symposium, Melbourne, Australia, November 2018. Oral Presentation.

26. Pryor D. Invited Speaker. Hypofractionation in prostate cancer radiotherapy. Uro-oncology Symposium, Gold Coast, Australia, August 2018. Oral Presentation.

27. Lamprecht B, Harvey J, McCluskey A, Eaves E, Lu G, Watson S, Barbour S, Lehman M, Mai T, Barry T, Brown E, Hargrave C. A dosimetric study evaluating different treatment techniques for whole

breast radiotherapy. PAH Symposium, Brisbane, Australia, August 2018. Poster Presentation.

Presentations

9

28. Johns E, Barry T, Bernard A, Brown E, Pinkham M. Optimising Dose Beyond the Target in Brain Stereotactic Radiotherapy. PAH Symposium, Brisbane, Australia, August 2018. Poster Presentation.

29. Wintour A, Porceddu S, Brown E, Yates P. Development of an Information Pamphlet for HPV Positive Oropharyngeal Cancer Patients. PAH Symposium, Brisbane, Australia, August 2018. Poster Presentation.

30. Jenkins M, Pinkham M, Lehman M, Baxter J, Barry T, Brown E, Lusk R, McBean A, Jones C, Clarke N, Olson S, Hall B, Foote M. Departmental Implications of Establishing a State-wide Intracranial Radiosurgery Service: The Gamma Knife® CoQ at the Princess Alexandra Hospital. PAH Symposium, Brisbane, Australia, August 2018. Oral Presentation.

31. Jenkins M, Pinkham M, Lehman M, Baxter J, Barry T, Brown E, Lusk R, McBean A, Jones C, Clarke N, Olson S, Hall B, Foote M. Departmental Implications of Establishing a State-wide Intracranial Radiosurgery Service: The Gamma Knife® CoQ at the Princess Alexandra Hospital. PAH Symposium, Brisbane, Australia, August 2018. Poster presentation.

32. Brown E. Exacting measures: comparing two imaging modalities for intracranial stereotactic radiation therapy. PAH Symposium, Brisbane, Australia, August 2018. Oral Presentation.

33. Nixon J. “I wouldn’t look in the mirror”: The distress and quality of life of living with head and neck lymphoedema. Australasian Lymphology Conference, Brisbane, Australia, May 2018. Oral Presentation.

34. Liu H, Porceddu S, Bernard A, Tam L, Milne R, Foote M, McGrath M, Cartmill B, Brown E, Burmeister B, Panizza B. Neck Dissection Rate in Node Positive HPV-Associated Oropharyngeal Carcinoma following (Chemo)radiotherapy. Australian and New Zealand Head and Neck Society (ANZHNS)-ISMR, Melbourne, Australia, July 2018. Oral Presentation.

35. Liu H, Bernard A, Brown E, Tam L, Foote M, Milne R, McGrath M, Rahbari R, Cartmill B, Panizza B, Porceddu S. Impact of smoking on (chemo)radiotherapy outcomes in HPV-associated oropharyngeal cancer. Australian and New Zealand Head and Neck Society (ANZHNS)-ISMR, Melbourne, Australia, July 2018. Poster Presentation.

36. Liu H. Invited speaker. Advancements in Head and Neck Radiation Therapy. Biennial Head and Neck Cancer Symposium, Brisbane, Australia, June 2018. Oral Presentation.

37. Cubis L, Ownsworth T, Pinkham M, Legg M, Foote M, Chambers S. The importance of staying connected: mediating and moderating effects of social groups on psychological wellbeing after brain tumour. COGNO ASM, Brisbane, Australia, October 2018. Oral Presentation.

38. Jardim A, Drew Z, Sadasivan A, Pinkham M, Foote M, Hall B, Olson S. Volumetric analysis of peri-lesional oedema after Gamma Knife for melanoma metastasis and its clinical correlation. COGNO ASM, Brisbane, Australia, October 2018. Poster Presentation.

39. Budgeon K, Moore J, Dunn N, Cuff K, Burmeister B, Olson S, Foote M, Pinkham MB. Glioblastoma multiforme in Queensland 2009-2014: a snapshot. COGNO ASM, Brisbane, Australia, October 2018. Poster Presentation.

40. Dulfikar A, Koh E, Lwin Z, Hovey E, Dhillon H, Arundell J, Pinkham E, Foo J, Hides J, Pinkham M, Naumann F. Baseline functional status in post-operative glioma patients prior to adjuvant

radiotherapy: relevance to participation in a supervised exercise program. COGNO ASM, Brisbane, Australia, October 2018. Poster Presentation.

Presentations

10

41. Dulfikar A, Pinkham E, Foo J, Hides J, Pinkham M, Lwin Z, Naumann F. A Tailored Exercise Intervention in People with Glioma: An EGGR Study Case Report. PAH Health Symposium, Brisbane, Australia, August 2018. Poster Presentation.

42. Pinkham M. Invited speaker. Update in melanoma brain metastases management. Stereotactic Interest Group of Australasia (SIGA) inaugural Annual Meeting, Melbourne, Australia, November 2018. Oral Presentation.

43. Pinkham M. Plenary Speaker. CNS Workshop (brain tumour biology), Brisbane Cancer Conference, Brisbane, Australia, November 2018. Session Chair.

44. Pinkham M. Invited speaker. Optimal sequencing of stereotactic radiosurgery and systemic therapy for brain metastases. COGNO ASM, Brisbane, Australia, October 2018. Oral Presentation.

45. Pinkham M. Invited Speaker. If Hippocampal-sparing Radiotherapy is the answer, what is the question? Pinnacle User’s Group Meeting, Brisbane, Australia, September 2018. Oral Presentation.

46. Pinkham M. Cancer Imaging and Technology, PAH Health Symposium, Brisbane, Australia, August 2018. Session Co-Chair.

47. Barry T. Invited speaker. Technical Challenges SBRT Spine, Inaugural SIGA Workshop, Melbourne, Australia, November 2018. Oral Presentation.

48. Brown S. Kidney SABR at Princess Alexandra Hospital – Initial experience overcoming a dosimetric challenge, Pinnacle Users Group Meeting, Brisbane, Australia, September 2018. Oral Presentation.

49. Brown E. Radiation Therapy in benign tumours, Pinnacle Users Group Meeting, Brisbane, Australia, September 2018. Oral Presentation.

50. Coles A. Parotid Gland and target volume overlap as a predictive model for parotid gland dose in VMAT RT to head and neck, Pinnacle Users Group Meeting, Brisbane, Australia, September 2018. Oral Presentation.

51. Johns E. SRT for Brain Mets at ROPAIR, Pinnacle Users Group Meeting, Brisbane, Australia, September 2018. Oral Presentation.

52. Watson S. A dosimetric study evaluating different treatment techniques for whole breast radiotherapy, Pinnacle Users Group Meeting, Brisbane, Australia, September 2018. Oral Presentation.

53. Boersen J. A retrospective departmental analysis of the accuracy and reproducibility of mouthpieces in H&N radiation therapy patients, QLD Radiation Therapy Weekend Conference, Townsville, Australia, October 2018. Oral Presentation.

54. Muscat E, Brown E, O’Connor P, Pryor D. Assessing breath hold reproducibility during abdominal SBRT using IntraFraction imaging, Australasian Elekta Users Meeting, Auckland, New Zealand, November 2018. Oral Presentation.

55. Liu E, Jones C. Virtual Octavius 4D Phantom in Pinnacle. Pinnacle Users Group Meeting, Brisbane, Australia, September 2018. Oral Presentation.

56. Lyons A, Alalade A, Foley H, Hall B, Pinkham M, Olson S, Foote M. Gamma Knife Radio-surgery for Trigeminal Neuralgia. PAH Health Symposium, Brisbane, Australia, August 2018. Poster Presentation.

Presentations

11

57. Effeney R. Risk of hippocampal metastases in small cell lung cancer: implications for hippocampal sparing cranial irradiation. IASLC 19th World Conference on Lung Cancer, Toronto, Canada, September 2018. Oral Presentation.

58. Porceddu S. Invited speaker. Organizing a Multidisciplinary Head and Neck Department, 6th World Congress of the International Federation of Head and Neck Oncologic Societies, Buenos Aires, Argentina, September 2018. Oral Presentation.

59. Porceddu S. Invited speaker. Management of Salivary Gland Cancer-role of radiation therapy. 6th World Congress of the International Federation of Head and Neck Oncologic Societies, Buenos Aires, Argentina, September 2018. Oral Presentation.

60. Porceddu S. Invited speaker. Osteoradionecrosis Prevention during radiotherapy. 6th World Congress of the International Federation of Head and Neck Oncologic Societies, Buenos Aires, Argentina, September 2018. Oral Presentation.

61. Porceddu S. Invited speaker. Larynx Cancer Radiation Oncology. 6th World Congress of the International Federation of Head and Neck Oncologic Societies, Buenos Aires, Argentina, September 2018. Oral Presentation.

62. Porceddu S. Invited speaker. Oral cavity cancer-Adjuvant treatment. 6th World Congress of the International Federation of Head and Neck Oncologic Societies, Buenos Aires, Argentina, September 2018. Oral Presentation.

63. Porceddu S. Invited speaker. State of the Art Radiotherapy. 10th Skin Cancer Summit and Master Classes, Brisbane, Australia, July 2018. Oral Presentation.

64. Porceddu S. Invited speaker, moderator and panelist. The International Federation of Head and Neck Oncologic Societies (IFHNOS) World Tour Faculty. The Philippine Society of Otolaryngology – Head and Neck Surgery, Manila, Philippines, October 2018. Oral Presentation.

65. Porceddu S. Invited speaker, moderator and panelist. The International Federation of Head and Neck Oncologic Societies (IFHNOS) World Tour Faculty. 18th National Meet of The Foundation for Head & Neck Oncology (FHNO), Kolkata, India, October 2018. Oral Presentation.

66. Porceddu S. Invited Speaker. The Great Debate. 18th National Meet of The Foundation for Head & Neck Oncology (FHNO), Kolkata, India, October 2018. Oral Presentation.

67. Porceddu S. Invited speaker, moderator and panelist. The International Federation of Head and Neck Oncologic Societies (IFHNOS) World Tour Faculty. Beijing, China, November 2018. Oral Presentation.

68. Porceddu S. Invited speaker, moderator and panelist. The International Federation of Head and Neck Oncologic Societies (IFHNOS) World Tour Faculty. Milan, Italy, November 2018. Oral Presentation.

69. O’Connor P, Brown E, Pryor D, Eaves E. Assessing reproducibility of breath-hold SBRT using intrafraction cone-beam CT. EPSM 2018, Adelaide, Australia, October 2018. Oral Presentation.

70. Charles P. Small field dosimetry using film in plastic phantoms – a Monte Carlo study. EPSM 2018, Adelaide, October 2018. Oral Presentation.

71. Noble C, Liu E, Perrett B, O’Connor P, Charles P. Applying the spatial resolution limits of the Octavius 1500 detector array to TPS dose calculations to isolate causes of low gamma pass rates in patient specific quality assurance. EPSM 2018, Adelaide, Australia, October 2018. Oral Presentation.

Presentations

12

72. Ramachandran P. A study on the dose to Contralateral breast with electronic compensators and conventional tangential fields, EPSM 2018, Adelaide, Australia, October 2018. Oral Presentation.

73. Webb L, Charles P. Assessment of an EPID based in-vivo dosimetry solution, EPSM 2018, Adelaide, Australia, October 2018. Oral Presentation.

74. Jones C, Seshadri V, Markwell T, Perrett B. Commissioning of an Elekta Leksell Gamma Knife (LGK) IconTM Cone Beam Computer Tomography (CBCT) and High Definition Motion Management (HDMM) System. EPSM 2018, Adelaide, Australia, October 2018. Oral Presentation.

75. Hanlon P, Charles P. Investigation into the inclusion of XVI kV Isocentre QA in the Daily Stereotactic Imaging QA. EPSM 2018, Adelaide, Australia, October 2018. Poster Presentation.

76. Hanlon P, Boyd J, Shakeshaft J, Charles P. MV Radiation Isocentre localization software QA Image. EPSM 2018, Adelaide, Australia, October 2018. Poster Presentation.

77. Seshadri V, Markwell T, Perrett B, Jones C. Implementation of Epid Based method to determine Focal Spot deviation in Elekta Linacs with Agility MLC. EPSM 2018, Adelaide, Australia, October 2018. Poster Presentation.

78. Seshadri V, Jones C, Markwell T, Perrett B. Investigation into coincidence of Gamma Knife® IconTM frame based and cone beam CT (CBCT) defined isocenters. EPSM 2018, Adelaide, Australia, October 2018. Poster Presentation.

79. Brown G, O’Connor P. Intrafraction Imaging: The Effect of MV Field Size on Image Quality. EPSM 2018, Adelaide, Australia, October 2018. Poster Presentation.

80. Perrett B, Jones C, Seshadri V, Markwell T. Commissioning of High Definition Motion Management on the Leksell Gamma Knife Icon. EPSM 2018, Adelaide, Australia, October 2018. Poster Presentation.

81. Liu E, Noble C, Perrett B, O’Connor P, Charles P. VeriSoft 7.1 Commissioning. EPSM 2018, Adelaide, Australia, October 2018. Poster Presentation.

82. Noble C, Harmer J, Perrett B, Horgan E, Charles P. EPR Dosimetry for measuring very small fields in modern radiotherapy. Promoted Seminar, University of Queensland Centre for Advanced Imaging, University of Queensland, Brisbane, Australia, December 2018. Poster Presentation.

83. Woody N, Tsai J, Caudell J, Ghanem A, Liu HY, Rybicki L, Joshi N, Geiger J, Lamarre E, Schymick M, Burkey B, Tam L, Dunlap N, Porceddu SV, Siddiqui F, Adelstein D, Lee L, Koyfman S. Improving prognostic classification in intermediate risk (INT) oral cavity squamous cell carcinoma (OCSCC): A Multi-Institutional Collaborative Study. ASTRO 2018, San Antonio, October 2018. Oral Presentation.

84. Ghanem A, Schymick M, Xia R, Tsai J, Lee N, Liu HY, Tam L, Woody N, Caudell J, Reddy C, Joshi N, Geiger J, Lamarre E, Dunlap N, Burkey B, Adelstein D, Koyfman S, Porceddu SV, Siddiqui F. The Influence of Smoking and Age on Pathologic Features and Outcomes in Oral Cavity Squamous Cell Cancer: A Multi-Institutional Collaborative Study. ASTRO 2018, San Antonio, USA, October 2018. Oral Presentation.

85. Koyfman S, Joshi N, Lamarre E, Tsai J, Schymick M, Liu HY, Tam L, Rybicki L, Dunlap N, Porceddu SV, Ghanem A, Siddiqui F, Caudell J, Lee N, Geiger J, Burkey B, Adelstein D, Woody N. Validating the AJCC 8th Edition of the Oral Cavity Cancer Staging System: A Multi-Institutional Collaborative Study. ASTRO 2018, San Antonio, USA, October 2018. Oral Presentation.

Presentations

13

86. Tsai J, Xie P, Woody N, Li X, McBride S, Caudell J, Ghanem A, Liu HY, Joshi N, Geiger J, Lamarre E, Schymick M, Tam L, Burkey B, Adelstein D, Dunlap N, Porceddu SV, Siddiqui F, Koyfman S, Lee N. Outcomes after salvage therapy in oral cavity squamous cell carcinoma (OCSCC) patients who developed locoregional failure (LRF) after definitive surgery and adjuvant (chemo)radiotherapy: a multi-institutional collaborative study. ASTRO 2018, San Antonio, USA, October 2018. Poster Presentation.

87. Liu HY, Tam L, Woody N, Caudell J, Reddy C, Ghanem A, Schymick M, Joshi N, Geiger J, Lamarre E, Burkey B, Adelstein D, Dunlap N, Siddiqui F, Koyfman S, Porceddu SV. Contralateral neck failure in well lateralized oral cavity cancer. ASTRO 2018, San Antonio, USA, October 2018. Oral Presentation.

88. Porceddu SV, Siddiqui F, Caudell J, Koyfman S, Tsai J, Liu HY, Reddy C, Rybicki L, Joshi N, Geiger J, Ghanem A, Schymick M, Burkey B, Lamarre E, Adelstein D, Lee N, Dunlap N, Woody N. Loco-regional relapse and predictors of outcome in early stage oral cavity cancers (pT1-2N0) treated with surgical monotherapy with or without neck dissection: a multi-institutional study. ASTRO 2018, San Antonio, USA, October 2018. Poster Presentation.

89. Liu HY. Invited speaker, High risk cutaneous SCC clinical trials. World Congress on Cancers of the Skin, Sydney, Australia, August 2018. Oral Presentation.

90. Liu HY, Stuart K, McLean K, Pryor D. Early Australian experience with Stereotactic Body Radiation Therapy (SBRT) in the management of Hepatocellular Carcinoma (HCC): Efficacy and toxicity. RANZCR ASM 2018, Canberra, Australia, October 2018. Oral Presentation.

91. Liu HY, Milne R, Lock G, Panizza BJ, Bernard A, Foote M, McGrath M, Brown E, Gandhi M, Porceddu SV. Utility of a deferred PET/CT scan to assess treatment response in Human Papillomavirus (HPV)-associated oropharyngeal cancer. RANZCR ASM 2018, Canberra, Australia, October 2018. Oral Presentation.

92. Liu HY, Porceddu SV, Bernard A, Tam L, Milne R, Foote M, McGrath M, Cartmill B, Brown E, Burmeister B, Panizza B. Neck Dissection Rate in Node Positive Human Papillomavirus Associated Oropharyngeal Carcinoma following Chemo-Radiotherapy. Australian and New Zealand Head and Neck Cancer Society, Melbourne, Australia, July 2018. Oral Presentation.

93. Foote M. Gamma Knife - Clinical Implications and Applications. Queensland Acoustic Neuroma Conference, Brisbane, Australia, August 2018. Oral Presentation.

94. Foote M. ’Tiger Territory’ - Stereotactic Spine Radiotherapy - Re-irradiation and Post-operative. Peter Mac SABR Symposium, Melbourne, Australia, November 2018. Oral Presentation.

95. Foote M. Spine SBRT. International Atomic Energy Agency Stereotactic Teaching Course. Melbourne, Australia, November 2018. Oral Presentation.

96. Foote M. Optimising management of melanoma brain metastases in the targeted era. International Stereotactic Radiosurgery Society Webinar series. November 2018. Oral Presentation.

97. Brown B. Invited Speaker. Patient-reported outcomes in routine care in Queensland. Brisbane Cancer Conference, Brisbane, Australia, November 2018. Oral Presentation

98. Liu H, Chan R, Cooney L, Schulz D, Catchpole N, Brown B, Nixon J, Brown E, Mahoney L, Johnson A. Putting the person front and centre, changing clinical practice. Convenors: Dr Bena Brown, Jodie Nixon, Annie Johnson, Dr Elizabeth Brown. 5th Biennial Head and Neck Cancer Symposium, Brisbane, Australia, June 2018. Oral Presentations.

Presentations

14

99. Pinkham E. What’s best for breast? Australasian Lymphology Conference, Brisbane, Australia, May 2018. Oral Presentation.

100. Pinkham E. Improving efficiency of service to pre-op breast cancer patients, Australasian Lymphology Conference, Brisbane, Australia, May 2018. Oral Presentation.

101. Manning S. Lymphoedema Patient Database – An 8 Year Review of Breast Cancer Patients. Australasian Lymphology Conference, Brisbane, Australia, May 2018. Poster Presentation.

102. Hides J, Mitchell E. Superior Vena Cava Obstruction – A challenging case study. Australasian Lymphology Conference, Brisbane, Australia, May 2018. Poster Presentation.

103. Lee YY. Modern approaches to radiation therapy – What the GP should know. General Practice Conference & Exhibition. Brisbane, Australia, September 2018. Oral Presentation.

104. Lee YY. Emerging role of SBRT in HCC. Australian Gastro-Intestinal Trial Group ASM, Liver SBRT Workshop, Brisbane, Australia, November 2018. Oral Presentation.

105. Ramachandran P. Invited Speaker. Electronic Brachytherapy. AMPICON 2018, Chennai, India, November 2018. Oral Presentation.

106. Brennan K, Brown E, Nixon J, Mahoney L, Wilton S. The magic power of our hands: Using manual lymphatic drainage to support the radiotherapy journey for head and neck cancer. Australasian Lymphology Conference, Brisbane, Australia, May 2018.

107. Noble C, Harmer J, Perrett B, Horgan E, Charles P. EPR Dosimetry for Measuring Very Small Fields in Modern Radiotherapy. 3rd Joint Asia Pacific EPR Society (APES) and International EPR Society (IES) Conference, Brisbane, Australia, September 2018. Poster Presentation.

Publications

15

1. Head and neck squamous cell carcinoma of unknown primary: Outcomes of a pre-defined institutional treatment policy in a region with a high prevalence of skin cancer. Huo M,

Panizza B, Bernard A, Porceddu S. Oral Oncology. 2018;77:43-48.

2. Exploring the prevalence and experience of mask anxiety for the person with head and neck cancer undergoing radiotherapy. Nixon JL, Cartmill B, Turner J, Pigott A E, Brown E, Wall LR, Ward EC, Porceddu SV. Med Radiat Sci. 2018;65(4):282-290.

3. In Regard to Beadle and Anderson. Le QT, Yom SS, Wee JTS, Lee AWM, Grau C, Grégoire V, Porceddu S, Welch JJ, Mehanna H. Int J Radiat Oncol Biol Phys. 2018;102(1):229-230.

4. Population Description and Clinical Response Assessment for Spinal Metastases: Part 2 of the SPIne Response Assessment in Neuro-Oncology (SPINO) Group Report. Laufer I, Lo SS, Chang EL, Sheehan J, Guckenberger M, Sohn MJ, Ryu S, Foote M, Muacevic A, Soltys SG, Chao S, Myrehaug S, Gerszten PC, Lis E, Maralani P, Bilsky M, Fisher C, Rhines L, Verlaan JJ, Schiff D, Fehlings MG, Ma L, Chang S, Parelukar WR, Vogelbaum MA, Sahgal A. Neuro-Oncology, 2018;20(9):1215-1224.

5. Intralesional PV-10 for the treatment of in-transit melanoma metastases-Results of a prospective, non-randomized, single center study. Read TA, Smith A, Thomas J, David M, Foote M, Wagels M, Barbour A, Smithers BM. J Surg Oncol. 2018;117(4):579-587.

6. A comparative study of three small-field detectors for patient specific stereotactic arc dosimetry. Webb LK, Inness EK, Charles PH. Australas. Phys. 2018;41(1):217-223.

7. Head and neck lymphedema management: Evaluation of a therapy program. Pigott A, Nixon J, Fleming J, Porceddu S. Head & Neck. 2018;40:1131–1137.

8. Radiotherapy for recurrent prostate cancer: 2018 Recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary group. Lieng H, Hayden AJ, Christie DRH, Davis BJ, Eade TN, Emmett L, Holt T, Hruby G, Pryor D, Shakespeare TP, Sidhom M, Skala M, Wiltshire K, Yaxley J, Kneebone A. Radiotherapy and Oncology. 2018;129(2):377-386.

9. The evolution and rise of stereotactic body radiotherapy (SBRT) for spinal metastases. Vellayappan VA, Chao ST, Foote M, Guckenberger M, Redmond KJ, Chang EL,

Mayr NA, Sahgal A, Lo SS. Expert Rev Anticancer Ther. 2018;3:1-14.

10. Moderate hypofractionation for prostate cancer: A user’s guide. Pryor D, Turner SL, Tai KH, Tang C, Sasso G, Dreosti M, Woo HH, Wilton L, Martin JM. J Med Imaging Radiat Oncol. 2018;62(2):232-239.

11. PROstate Multicentre External beam radiotherapy Using a Stereotactic boost: the PROMETHEUS study protocol. Richardson M, Sidhom M, Gallagher S, Grand M, Pryor D, Bucci J, Wilton L, Arumugam S, Keats S, Martin JM. BMC Cancer. 2018;18(1):588.

12. Development of Quality Indicators to Monitor Radiotherapy Care for Men with Prostate Cancer: A modified Delphi Method. Tsiamis E, Millar J, Baxi S, Borg M, De Leso P, Elsaleh H, Foroudi F, Higgs B, Holt T, Martin J, Moretti K, Pryor D, Skala M, Evans S. Radiotherapy Oncol. 2018;128(2):308-314.

13. A mixed methods examination of distress and person-centred experience of head and neck lymphoedema. Nixon J, Pigott A, Cartmill B, Turner J, Fleming J, Porceddu S. Oral Oncology. 2018;83:18-24.

Publications

16

14. Palliative chemoradiotherapy versus radiotherapy alone for dysphagia in advanced oesophageal cancer: a multicentre randomised controlled trial (TROG 03.01). Harvey JA, Stephens S, Au HJ, O’Callaghan CJ, Kneebone A, Ngan SY, Ward IG, Roy R, Smith JG, Nijjar T, Biagi JJ, Mulroy LA, Wong R, on behalf of the TROG 03.01/CCTG ES.2 group. Lancet Gastroenterol Hepatol 2018;3(2):114-124

15. Non-small cell lung cancer brain metastasis screening in the era of positron emission tomography-CT staging: Current practice and outcomes. Diaz ME, Debowski M, Hukins C, Fielding D, Fong KM, Bettington CS. J Med Imag Radiat Oncol 2018;62:383–388.

16. Deep inspiration breath hold in breast cancer: Development and analysis of a patient experience questionnaire. Beaton N, Watson S, Browne P, Sharma H, Mai T, Harvey J, Bernard A, Brown E, Hargrave C, Lehman M. J Med Imag Radiat Oncol. 2018;62(6):854-860

17. Failure Modes and Effects Analysis in a paperless radiotherapy department. Frewen H, Brown E, Jenkins M, O’Donovan A. J Med Imag Radiat Oncol. 2018;62(5):707-715.

18. An ex vivo human tumour assay reveals distinct patterns of EGFR trafficking in squamous cell carcinoma correlating to therapeutic outcomes. Joseph SR, Gaffney D, Barry R, Hu L, Banushi B, Wells JW, Lambie D, Strutton G, Porceddu SV, Burmeister B, Leggatt GR, Schaider H, Dolcetti R, Frazer IH, Saunders NA, Foote M, Soyer HP, Simpson F. Journal of Investigative Dermatology. 2018;139(1):213-223.

19. A mixed methods examination of distress and person-centred experience of head and neck lymphoedema. Nixon, JL, Pigott AE, Cartmill, B, Turner J, Fleming J, Porceddu SV. Oral Oncology. 2018;83:18-24.

20. HPV-16 viral load in oropharyngeal squamous cell carcinoma using digital PCR. Antonsson A, Knight L, Panizza BJ, Porceddu, SV, Emmett S, Whiteman DC. Acta Oto-Laryngologica. 2018;138(9):1-5.

21. Sexual behaviour, HPV status and p16 expression in oropharyngeal and oral cavity squamous cell carcinomas: a case-case comparison study. Emmett S, Boros S, Whiteman DC,

Porceddu SV, Panizza BJ, Antonsson A. Journal of General Virology. 2018;99(6):783-789.

22. Postoperative Concurrent Chemoradiotherapy Versus Postoperative Radiotherapy in High-Risk Cutaneous Squamous Cell Carcinoma of the Head and Neck: The Randomized Phase III TROG 05.01 Trial. Porceddu SV, Bressel M, Poulsen M, Stoneley A, Veness MJ Kenny LM, Wratten C, Corry J, Cooper S, Fogarty GB, Collins M, Collins MK, Macann AMJ, Milross CG, Penniment MG, Liu HY, King MT, Panizza BJ, Rischin D. Journal of Clinical Oncology. 2018;36(13):1275-1283.

23. Head and neck lymphedema management: evaluation of a therapy program. Pigott A, Nixon J, Fleming J, Porceddu S. Head and Neck. 2018;40(6):1131-1137.

24. Commentary: Stereotactic Body Radiotherapy for Spinal Metastases at the Extreme Ends of the Spine: Imaging-Based Outcomes for Cervical and Sacral Metastases. Vellayappan B,

Tan D, Foote M, Redmond KJ, Lo SS. Neurosurgery. 2018 Oct 8;nyy428.

25. Economic Analysis of a Three-Arm RCT Exploring the Delivery of Intensive, Prophylactic Swallowing Therapy to Patients with Head and Neck Cancer During (Chemo)Radiotherapy. Wall L, Kularatna S, Ward E, Cartmill B, Hill A, Isenring E, Byrnes J, Porceddu S. Dysphagia. 2018;pp1-13.

Publications

17

26. Patterns of failure following dose-escalated chemoradiotherapy for fluorodeoxyglucose positron emission tomography staged squamous cell carcinoma of the oesophagus.

Effeney R, Shaw T, Burmeister BH, Burmeister E, Harvey J, Mai GT, Barbour A, Thomas J, Smithers BM, Pryor D. Clinical Oncology. 2018;30(10):642-649.

27. TROG 15.03 phase II clinical trial of Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney. Siva S, Chesson B, Bressel M, Pryor D, Higgs B, Reynolds HM, Hardcastle N, Montgomery R, Vanneste B, Khoo V, Ruben J, Lau E, Hofman MS, De Abreu Lourenco R, Sridharan S, Brook NR, Martin J, Lawrentschuk N, Kron T, Foroudi F. BMC Cancer. 2018;18(1):1030.

28. Evaluation of Kidney Motion With and Without a Pneumatic Abdominal Compression Belt: Considerations for Stereotactic Radiotherapy. West K, Russo M, Brown E, Barry T, Hargrave C, Pryor D. Med Imaging Radiat Oncol. 2018;62(1):128-132.

29. Communicating Actively Responding Empathically (CARE): Comparison of communication training workshops for health professionals working in cancer care. Nixon J, Gray L, Turner J, Bernard A, Scaife J, Cartmill B. Journal of Cancer Education. 2018;pp1-7.

30. Patient perceptions of living with head and neck lymphoedema and the impacts to swallowing, voice and speech function. Jeans C, Ward EC, Cartmill B, Vertigan AE, Pigott AE, Nixon JL, Wratten C. European Journal of Cancer Care. 2018;28(1):e12894-12903

31. Content analysis of rehabilitation goals for patients following non-surgical head and neck cancer treatment. Barnhart MK., Ward EC, Cartmill B, Nund R, Robinson RA, Chandler SJ, Smee RI. Supportive Care in Cancer, 2019;27(2):639-647.

32. Treatment toxicities and their impact on oral intake following non-surgical management for head and neck cancer: a 3-year longitudinal study. Barnhart MK, Robinson RA, Simms VA, Ward EC, Cartmill B, Chandler SJ, Smee RI. Supportive Care Cancer, 2018;26(7):2341-2351.

33. Does a pre-treatment education model impact on swallow and nutrition outcomes in head and neck cancer patients receiving (chemo)radiotherapy? Cartmill B, Wall L, Sim W, Fong E, Ward EC, Johnson A, Brown A, Porceddu S. Dysphagia. 2018;33:501.

34. Neck dissection rate in node positive human papillomavirus associated oropharyngeal carcinoma following chemoradiotherapy. Porceddu SV, Liu H, Bernard A, Tam L, Milne R, Foote M, McGrath ML, Cartmill B, Brown E, Burmeister B, Panizza B. Journal of Clinical Oncology. 2018;36(15):S6067-6067.

35. Determination of dose enhancement caused by AuNPs with Xoft Axxent Electronic eBx and conventional brachytherapy in vitro study. Shahhoseini E, Ramachandran P, Patterson WR, Geso M. Int. J Nanomedicine. 2018;13:5733-5741.

* Closed during the 2018 year^ Open during the 2018 year

ALLG Australian Leukaemia and Lymphoma GroupALTG: Australasian Lung Cancer Trials GroupANZMTG: Australia New Zealand Melanoma Trials GroupANZUP: Australia New Zealand Urogenital and Prostate Cancer Trials Group BIG: Breast International GroupEORTC: European Organisation for Research and Treatment of CancerICR (UK): Institution of Cancer Research (UK)TROG: Trans Tasman Radiation Oncology Group

Acknowledgements in preparing this reportMelissa Scott, Harish Sharma, Andrew Puffett and the entire PAH Radiation Therapy Research Team

Collaborative Trials Portfolio

18

STUDY PHASE SPONSOR / INVESTIGATOR DISEASE SITE STATUS

COMBI-RT I/II ANZMTG Melanoma Open to recruitment

EXPERT^ III BTG/BIG Breast Open to Recruitment

FASTRACK II II TROG/ANZUP Renal Open to Recruitment

HER-O^ II TROG Breast Open to Recruitment

OUTRUN^ II TROG Lung Open to Recruitment

RAIDER II ICR (UK)/TROG Bladder Open to Recruitment

RAPPORT Ib/II Investigator Renal Open to Recruitment

ROAM^ III EORTC/TROG Brain Open to Recruitment

RTN2 III ANZMTG/TROG Melanoma Open to Recruitment

SARC032^ II SARC Sarcoma Open to Recruitment

SC.24^ III TROG/CCTG Mets Open to Recruitment

Split Course Prostate II Investigator Prostate Open to Recruitment

CORE* II/III ICR (UK)/TROG Oligometastases Follow-up

DCIS III TROG/BIG Breast Follow-up

ENZARAD* III ANZUP/TROG Prostate Follow-up

HART*^ II TROG Breast Follow-up

HPV* III TROG H+N Follow-up

LOW GRADE GLIOMA III EORTC/TROG Brain Follow-up

NIMORAL III EORTC/TROG H+N Follow-up

PROMETHEUS* II Investigator Prostate Follow-up

RAVES III TROG Prostate Follow-up

SAFRON II* II TROG/ALTG Mets Follow-up

STARS III TROG Breast Follow-up

STARS (Pilot) II Investigator Breast Follow-up